OWLT Quote, Financials, Valuation and Earnings

Apyx Medical Corp. has a net margin of 12.58% compared to Owlet, Inc.'s net margin of -15.18%. Owlet, Inc.'s return on equity of -- beat Apyx Medical Corp.'s return on equity of -146.08%.

Owlet, Inc. has a consensus price target of $17.00, signalling upside risk potential of 57.85%. On the other hand Apyx Medical Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 56.25%. Given that Owlet, Inc. has higher upside potential than Apyx Medical Corp., analysts believe Owlet, Inc. is more attractive than Apyx Medical Corp..

Owlet, Inc. has a beta of 1.713, which suggesting that the stock is 71.275% more volatile than S&P 500. In comparison Apyx Medical Corp. has a beta of 1.592, suggesting its more volatile than the S&P 500 by 59.181%.

Owlet, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apyx Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Owlet, Inc. pays -- of its earnings as a dividend. Apyx Medical Corp. pays out -- of its earnings as a dividend.

Owlet, Inc. quarterly revenues are $32M, which are larger than Apyx Medical Corp. quarterly revenues of $12.9M. Owlet, Inc.'s net income of $4M is higher than Apyx Medical Corp.'s net income of -$2M. Notably, Owlet, Inc.'s price-to-earnings ratio is -- while Apyx Medical Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Owlet, Inc. is 1.80x versus 3.22x for Apyx Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Masimo Corp. has a net margin of 12.58% compared to Owlet, Inc.'s net margin of 14.46%. Owlet, Inc.'s return on equity of -- beat Masimo Corp.'s return on equity of -19.18%.

Owlet, Inc. has a consensus price target of $17.00, signalling upside risk potential of 57.85%. On the other hand Masimo Corp. has an analysts' consensus of $178.75 which suggests that it could grow by 2.32%. Given that Owlet, Inc. has higher upside potential than Masimo Corp., analysts believe Owlet, Inc. is more attractive than Masimo Corp..

Owlet, Inc. has a beta of 1.713, which suggesting that the stock is 71.275% more volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.165%.

Owlet, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Owlet, Inc. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.

Owlet, Inc. quarterly revenues are $32M, which are smaller than Masimo Corp. quarterly revenues of $371.5M. Owlet, Inc.'s net income of $4M is lower than Masimo Corp.'s net income of $53.7M. Notably, Owlet, Inc.'s price-to-earnings ratio is -- while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Owlet, Inc. is 1.80x versus 5.52x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Nephros, Inc. has a net margin of 12.58% compared to Owlet, Inc.'s net margin of 7.07%. Owlet, Inc.'s return on equity of -- beat Nephros, Inc.'s return on equity of 16.22%.

Owlet, Inc. has a consensus price target of $17.00, signalling upside risk potential of 57.85%. On the other hand Nephros, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 62.5%. Given that Nephros, Inc. has higher upside potential than Owlet, Inc., analysts believe Nephros, Inc. is more attractive than Owlet, Inc..

Owlet, Inc. has a beta of 1.713, which suggesting that the stock is 71.275% more volatile than S&P 500. In comparison Nephros, Inc. has a beta of 1.397, suggesting its more volatile than the S&P 500 by 39.715%.

Owlet, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nephros, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Owlet, Inc. pays -- of its earnings as a dividend. Nephros, Inc. pays out -- of its earnings as a dividend.

Owlet, Inc. quarterly revenues are $32M, which are larger than Nephros, Inc. quarterly revenues of $4.8M. Owlet, Inc.'s net income of $4M is higher than Nephros, Inc.'s net income of $337K. Notably, Owlet, Inc.'s price-to-earnings ratio is -- while Nephros, Inc.'s PE ratio is 28.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Owlet, Inc. is 1.80x versus 2.40x for Nephros, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of 12.58% compared to Owlet, Inc.'s net margin of -316.61%. Owlet, Inc.'s return on equity of -- beat Plus Therapeutics, Inc.'s return on equity of --.

Owlet, Inc. has a consensus price target of $17.00, signalling upside risk potential of 57.85%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1861.48%. Given that Plus Therapeutics, Inc. has higher upside potential than Owlet, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Owlet, Inc..

Owlet, Inc. has a beta of 1.713, which suggesting that the stock is 71.275% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Owlet, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Owlet, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Owlet, Inc. quarterly revenues are $32M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Owlet, Inc.'s net income of $4M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Owlet, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Owlet, Inc. is 1.80x versus 4.49x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.